SandboxAQ, Deloitte Strengthen Partnership to Transform Healthcare

SandboxAQ has announced the expansion of its strategic alliance with Deloitte, bringing SandboxAQ’s AI-driven LQM (Large Quantitative Models) simulation solutions to organizations globally. This collaboration aims to accelerate product development across various industries, particularly biopharma, leveraging both SandboxAQ’s advanced AQBioSim and AQChemSim solutions, along with Deloitte’s vast service capabilities in data and life sciences.

Andrew McLaughlin, Chief Operating Officer at SandboxAQ, expressed excitement over the expanded partnership, stating, “AI simulation with Large Quantitative Models represents the next evolution of AI, transforming how organizations create value for their customers in ways that Large Language Models cannot.”

The integration of LQMs with Deloitte’s Atlas AI™ knowledge graph will enable SandboxAQ’s scientists to extract new, clinically relevant hypotheses, enhancing drug discovery processes. This collaboration combines Deloitte’s engineering expertise and industry knowledge to streamline and accelerate drug discovery, utilizing AI-powered molecular simulations for deeper insights into drug development and treatment responses.

Aditya Kudumala, Principal at Deloitte Consulting LLP, emphasized the strength of the partnership, saying, “Together, we aim to advance drug discovery and materials science for leading academic, commercial, and public sector entities.”

With this expanded alliance, the companies aim to drive innovation and efficiency in drug development, ultimately reshaping the healthcare and life sciences sectors.